You just read:

Recent Progressive Forms of Multiple Sclerosis Chart Audit Provides Evidence That the Institute for Clinical and Economic Review's Comparators of Interest for Novartis' Siponimod Assessment May Not Be Relevant for the Not Active Secondary Progressive Multiple Sclerosis Segment

News provided by

Spherix Global Insights

Nov 13, 2018, 10:14 ET